Quick Answer
Sigyn Therapeutics, Inc. reported Gross Profit of $107.7 thousand for fiscal year 2019.
Sigyn Therapeutics, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2019 | $107.7K | +477.7% |
| 2018 | $18.6K | +9.6% |
| 2017 | $17.0K | -11.8% |
| 2015 | $19.3K | +7.7% |
| 2014 | $17.9K | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2020 | $2.0K | -91.6% | +312.8% |
| March 31, 2020 | $493.00 | -98.5% | -98.0% |
| September 30, 2019 | $24.1K | -69.0% | -49.3% |
| June 30, 2019 | $47.5K | +723.2% | +47.0% |
| March 31, 2019 | $32.3K | +139.9% | -58.5% |
| September 30, 2018 | $77.8K | -50.6% | +1248.2% |
| June 30, 2018 | $5.8K | -97.7% | -57.2% |
| March 31, 2018 | $13.5K | -93.0% | -91.4% |
- Sigyn Therapeutics, Inc. showed an increase of +477.7% in Gross Profit compared to the prior fiscal year.
- Over the 2014–2019 period, Sigyn Therapeutics, Inc.’s gross profit has grown by 501.3% (from $17.9 thousand to $107.7 thousand).
- The most recent figure is from Sigyn Therapeutics, Inc.’s fiscal year 2019 report (Form 10-K), filed with the SEC on March 30, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: